Overview

Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study is being performed to test if the use of high dose of cetuximab in combination with irinotecan overcomes the resistance seen with standard dose of cetuximab plus irinotecan in patients with wild type KRS tumors that have advanced colon or rectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Camptothecin
Cetuximab
Irinotecan